SQZ play: Roche dou­bles down on a $1.37B-plus deal for a new ap­proach to im­muno-on­col­o­gy out of Bob Langer's lab

What­ev­er Roche $ROG learned about SQZ over the last 33 months clear­ly on­ly whet­ted their ap­petite for much, much more.

This morn­ing SQZ is un­veil­ing a re­vise-re­place-and-ex­pand de­vel­op­ment pact with the Wa­ter­town, MA-based biotech, one of many to emerge from the lab of MIT’s Bob Langer. 

In this new deal Roche is putting up $125 mil­lion for an up­front and near-term mile­stones in a col­lab­o­ra­tion deal em­bed­ded with $1 bil­lion in de­vel­op­ment goal mon­ey. An­oth­er $250 mil­lion is on the line for each new ther­a­py that man­ages to make it all the way to an ap­proval.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN